Connection

NANCY WEIGEL to Cell Proliferation

This is a "connection" page, showing publications NANCY WEIGEL has written about Cell Proliferation.
Connection Strength

0.976
  1. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr; 151(4):1409-17.
    View in: PubMed
    Score: 0.188
  2. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009 May; 150(5):2046-54.
    View in: PubMed
    Score: 0.175
  3. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 2017 Jul 04; 8(27):44447-44464.
    View in: PubMed
    Score: 0.079
  4. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
    View in: PubMed
    Score: 0.070
  5. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014 Sep; 54:49-59.
    View in: PubMed
    Score: 0.064
  6. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.057
  7. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol. 2013 Jan; 42(1):35-43.
    View in: PubMed
    Score: 0.057
  8. 1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate. 2011 Jan 01; 71(1):98-110.
    View in: PubMed
    Score: 0.050
  9. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.044
  10. Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. Mol Cell Endocrinol. 2007 Feb; 265-266:157-61.
    View in: PubMed
    Score: 0.038
  11. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.037
  12. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.037
  13. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.033
  14. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.
    View in: PubMed
    Score: 0.016
  15. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther. 2009 Jul; 8(7):1787-98.
    View in: PubMed
    Score: 0.011
  16. PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). Steroids. 2007 Dec; 72(14):930-8.
    View in: PubMed
    Score: 0.010
  17. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids. 2006 Feb; 71(2):102-15.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.